Phapros Records Over 2000% YoY EBITDA Surge and Double-Digit Sales Growth in Q3 2025

JAKARTA, December 01, 2025—Amidst the continuously developing dynamics of the health industry, including challenges in several sales segments, PT Phapros Tbk (PEHA), successfully recorded positive performance up to the third quarter of 2025. Based on the limited review financial report published by the Company on November 30, 2025, PEHA successfully booked consolidated revenue of Rp683.6 billion, growing 19.5 percent YoY.

This sales growth was primarily driven by the improved performance of branded drug products, including prescription drugs (ethical products) and over-the-counter drugs (OTC), as well as the Generic drugs segment. Furthermore, sales growth contributions were also obtained from the subsidiary within the group, namely PT Lucas Djaja. Several leading products in the Branded Drug sector, including Antimo Group, Fitogen, Noza, Dextamine, and Pehacain, were the contributors that supported the increase in sales and the improvement of the Company's margin. Additionally, the therapy line for Tuberculosis (TB) treatment through OAT products and malaria therapy also provided a positive contribution to the Company's sales performance in the Generic drug segment.

The Company's EBITDA and Net Profit Performance

Aside from sales, one of the most significant achievements in Q3 2025 was the sharply increased EBITDA of 2748 percent YoY from a negative position in 2024. The Company successfully recorded an EBITDA of Rp88.6 billion. This performance increase was mainly driven by sales growth, product portfolio optimization, and the implementation of comprehensive efficiency measures across the Company. This efficiency included not only the production process in Manufacturing but also Marketing activities, and the strengthening of the supporting function department in optimizing work processes and controlling costs. In line with this, net profit also turned positive to Rp7.7 billion, an increase of 111 percent YoY from a loss position in 2024. This achievement reflects a strong performance recovery through a number of strategies implemented, supported by a decrease in financial burden and the effectiveness of the cost efficiency program run by the Company.

Comprehensive Efficiency Across All Lines

Operational efficiency was one of the drivers of the Company's performance improvement this year. Cost of Goods Sold (COGS) to sales was recorded to have decreased by 4.8 points, while operating expenses were successfully suppressed by 4.3 percent YoY, in line with the cost restructuring program and the focus on selling high-margin products. These strategic steps made the Company's cost structure healthier and supported sustainable performance. On the other hand, consolidated operational cash flow was recorded as positive Rp53.5 billion, reflecting a maintained and reasonably healthy liquidity condition.

The Acting President Director of PEHA, Ida Rahmi Kurniasih, stated that the achievement up to September 2025 is the result of the consistent transformation the Company has been running since the beginning of this year. "This performance shows that internal improvement efforts in the Marketing aspect, cost efficiency, and focusing on high-value products have a real impact. We are optimistic that this positive trend will continue until the end of the year," said Ida.

New Product Launch

Ida Rahmi added that the Company will strengthen its product portfolio in the next few years as part of continuous innovation. On the same occasion, Ida conveyed that PEHA will launch a new drug for the treatment of erectile dysfunction and male stamina in December 2025 with the brand X-GRAREX ODF. According to her, this product offers differentiation through a more modern formulation and more practical packaging compared to similar products. The launching of this new product is evidence of the Company's effort to continue to advance and compete in the future through a strategy of rejuvenating its product portfolio every year. The presence of this new product is also expected to expand Phapros' reach in the adult therapy segment while providing a positive contribution to sales performance in the coming year. In addition to product innovation, the Company is also continuously working to improve distribution quality to expand market penetration. This is also the focus of Phapros' strategy in maintaining positive growth until the end of the year, concluded Ida.